#LegendNews: Legend Biotech will host a webcast to announce 2025 first-quarter financial results on May 13 at 8 a.m. ET. Register to join here: investors.legendbiotech.com/news-releases/… $LEGN #WeAreLegend #FinancialResults

It’s #OncologyNursingMonth, and we’re celebrating the extraordinary oncology nurses on the front lines of patient care. We witness the crucial role these #HealthcareHeroes play in the fight against cancer; we’re honored to work alongside such dedicated professionals. #CancerCare

We are thrilled to announce Legend Biotech is an official partner of @NerdlandBe Festival 2025! 🔬We can't wait to connect with fellow #Science enthusiasts, families, and the vibrant #Nerdland community. Check out our lineup of Legendary speakers: legendbiotech.eu/nerdlandfestiv…

#LegendNews: Today, we shared our 2025 first-quarter financial results, with insights from our CEO, Ying Huang. Read the highlights and more here: investors.legendbiotech.com/news-releases/… #CellTherapy #CART

Welcome to Legend Biotech Medical Affairs! We are dedicated to sharing updates on the research and clinical development of innovative cellular therapies to improve the lives of patients. We hope you will follow us and look forward to the scientific exchange. See our community guidelines. #CellRx

We are thrilled to announce that our #CART #CellTherapy for patients with #MultipleMyeloma has achieved a record-high manufacturing success rate of 97% at our facility in Raritan, NJ. At Legend Biotech, we push beyond boundaries every day to advance our transformational therapy.

#LegendNews: Join us Sunday, June 1, 6 p.m. CT (7 p.m. ET) at ASCO Annual Meeting for Legend Biotech’s Investor Event in Chicago. Hear the latest on our clinical progress and #CellTherapy pipeline. investors.legendbiotech.com/news-releases/… #ASCO25 #Investors #Biotech #CART $LEGN

#LegendNews: Our state-of-the-art Tech Lane facility in Belgium has begun clinical production of our #CART #CellTherapy! Here's to a future where more patients can benefit from the transformative potential of cell therapy! 🚀

Our CEO, Ying Huang, spoke with Genetic Engineering & Biotechnology News about our leadership in #CellTherapy for #MultipleMyeloma & how we're expanding access to CAR-T therapies. Learn more: genengnews.com/topics/cancer/… #CART #CellTherapy

We will present long-term data on our #CART therapy for multiple myeloma at ASCO and new data at European Hematology Association. Visit our ASCO exhibit #11113 to learn about our transformative therapy that has treated ~6K patients to date and our work in #SolidTumors. investors.legendbiotech.com/news-releases/…

Today is #WorldBloodCancerDay. At Legend Biotech, we stand in solidarity with patients, families, and healthcare professionals impacted by blood cancers like #MultipleMyeloma. We are committed to advancing transformative therapies that improve patient outcomes. #CellTherapy

The ASCO Annual Meeting begins today! Our CEO, Ying Huang, shares his thoughts on the upcoming conference and previews the abstracts we will present regarding our #CART #CellTherapy for #MultipleMyeloma. If you’re attending, visit us at booth #11113. investors.legendbiotech.com/news-releases/…

#SavetheDate! June 1 is #NationalCancerSurvivorsDay. 🌟 At Legend Biotech, we honor the strength and resilience of cancer survivors. Their journeys inspire our commitment to advancing #CellTherapies for a brighter future and long-term survival. #PatientImpact #CART #CellTherapy

#ICYMI: Our CEO, Dr. Ying Huang, met with BiotechTV at #ASCO25 to discuss new long-term OS data from our #CART #CellTherapy trials to treat #MultipleMyeloma, expanding pipeline for #SolidTumors and more. Watch now: bit.ly/3ZMsWjD #OncologyInnovation

That’s a wrap on ASCO 2025! ✅ At this year’s meeting, we showcased new data on #CART #CellTherapy in relapsed/refractory #MultipleMyeloma, and presented exciting progress in solid tumors. Thanks to the ASCO community for a productive and collaborative #ASCO2025!

Our #LEGENDary team in Belgium recently took part in the Kom op tegen Kanker cycling challenge to raise support for vital #CancerResearch. 🚴‍♂️ Over 4 days, they pedaled with purpose to cycle 1,000 km. Congrats to the entire team! #WeAreLegend #CyclingForACause

Legend Biotech is at the European Hematology Association 2025 Congress! Join us June 12, 2025, 17:00-18:15 CEST for an encore oral presentation of our groundbreaking five-year survival data for our #CART #CellTherapy in relapsed/refractory #MultipleMyeloma.

Our CEO Dr. Ying Huang met with @OncoDaily at the #ASCO2025 Annual Meeting to discuss the groundbreaking long-term CARTITUDE-1 data generated by our #CART #CellTherapy for #MultipleMyeloma. Watch the full clip: youtu.be/pwsSyv2d_xQ?si…

At #NERDLand2025, our #LEGENDary team connected with future scientists through our CAR-T Showcase Experience & inspiring sessions on the Talent Stage. Our interactive installations shared insights into our work in #CellTherapy and bringing transformative science to patients.

#CARTaccess news: The FDA has removed REMS requirements for BCMA- & CD19-targeted CAR-Ts. This pivotal milestone creates faster access and broader availability in community settings and makes CAR‑T more practical, scalable & patient-centric.